Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM2 | O94759 | 4/20 | 0.72 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.72 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.71 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.59 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.59 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | APEX1 | P27695 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294402 | 0.90 | TRPM2 (0.83) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL294403 | 0.90 | TRPM2 (0.83) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL2778920 | 0.85 | TRPM2 (0.81) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL29401064 | 0.85 | TRPM2 (0.81) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL2778922 | 0.85 | TRPM2 (0.81) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL13320663 | 0.85 | TRPM2 (0.64) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL30387813 | 0.85 | TRPM2 (0.64) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL4185775 | 0.85 | TRPM2 (0.64) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL4185773 | 0.85 | TRPM2 (0.64) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL28809051 | 0.84 | TRPM2 (1.00) | TRPM2LTB4RTRPA1TRPM8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9561201-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2017-02-07 | — | — | US | disclosed |
| US-9561201-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2017-02-07 | — | — | US | disclosed |
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-12-04 | — | — | US | disclosed |
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-12-04 | — | — | US | disclosed |
| US-8765812-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-07-01 | — | — | US | disclosed |
| US-8765812-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-07-01 | — | — | US | disclosed |
| US-20100130497-A1 | Therapeutic Compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| US-20090124669-A1 | Structural Analogues of Avenanthramides, Their Use in Compositions Useful in the Treatment of Dermatological Disorders | RELIVIA S.R.L | 2009-05-14 | — | — | US | disclosed |
| US-20090124669-A1 | Structural Analogues of Avenanthramides, Their Use in Compositions Useful in the Treatment of Dermatological Disorders | RELIVIA S.R.L | 2009-05-14 | — | — | US | disclosed |
| WO-2008003141-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | NFATC1, AADAC, NAT1 | TRPM2 1034/4885LTB4R 533/4885TRPA1 78/4885 |
| US-20090124669-A1 | Structural Analogues of Avenanthramides, Their Use in Compositions Useful in the Treatment of Dermatological Disorders | OAT, HLA-DRB1, CUTA | TRPM2 2302/4885LTB4R 689/4885TRPA1 3855/4885 |
| US-20100130497-A1 | Therapeutic Compounds | NFATC1, NAT1, AADAC | TRPM2 1042/4885LTB4R 491/4885TRPA1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.